01 The non-alcoholic steatohepatitis clinical trials market is indirectly exposed to supply chain disruptions due to its dependence on global networks for investigational drug manufacturing, clinical trial materials, laboratory supplies, and logistics. Disruptions in the procurement of active pharmaceutical ingredients, diagnostic kits, and clinical research equipment can delay patient enrollment, trial execution, and regulatory timelines across multiple regions. The market is demonstrating a stair-step recovery, supported by diversified supplier networks, decentralized clinical trial models, digital monitoring technologies, and strategic investments in resilient global clinical research infrastructure.
01 AI-Driven Biomarker Integration The growing adoption of artificial intelligence is changing how non-alcoholic steatohepatitis clinical trials identify eligible patients and monitor disease progression. Trial sponsors are increasingly integrating AI-based imaging analysis, digital pathology, and biomarker-driven patient stratification to improve trial efficiency and reduce screen failure rates. This transition is enabling more accurate endpoint assessment, faster recruitment, and improved decision-making throughout clinical development. For example, Perspectum uses AI-powered imaging technologies to support liver disease assessment and patient selection in NASH research.
02 Rising Adoption of Combination Therapies is Reshaping Clinical Development Increasing understanding of the complex mechanisms underlying NASH is driving a shift from single-drug approaches toward combination therapy clinical trials. Pharmaceutical companies are evaluating therapies targeting fibrosis, inflammation, and metabolic dysfunction simultaneously to improve treatment outcomes and address diverse patient populations. This transition is expanding collaborative research strategies and creating more comprehensive clinical development programs across the industry.
01 Increasing Use of Non-invasive Biomarkers and Expansion of Combination Therapy Development Drives Market The growing adoption of non-invasive biomarkers and imaging technologies is driving the non-alcoholic steatohepatitis clinical trials market by reducing dependence on repeated liver biopsies during patient screening and monitoring. Advanced MRI-PDFF, transient elastography, and blood-based biomarkers enable faster identification of eligible patients and improve participant retention throughout clinical studies. This shortens enrollment timelines and enhances operational efficiency for sponsors conducting global multicenter trials.The increasing focus on combination therapies is driving the market by creating demand for more complex and larger clinical studies. Since NASH involves fibrosis, inflammation, and metabolic dysfunction, developers are evaluating multiple mechanisms of action within a single treatment regimen to improve efficacy. This has increased the number of adaptive trial designs, dose-combination studies, and global Phase II and III programs.
01 Dependence on Liver Biopsy Endpoints and High Clinical Trial Failure Rates Restrain Market Expansion The continued reliance on liver biopsy as a primary efficacy endpoint restrains the non-alcoholic steatohepatitis clinical trials market by increasing trial complexity and patient burden. Biopsy procedures are invasive, costly, and often discourage patient participation and long-term follow-up. This leads to slower enrollment, higher dropout rates, and extended study timelines.The high failure rate of investigational NASH therapies and evolving regulatory expectations increases development risks for sponsors. Many drug candidates fail to demonstrate meaningful improvements in fibrosis or NASH resolution during late-stage studies, resulting in program discontinuation and financial losses. This reduces investment confidence and delays the introduction of new therapies.
01 Decentralized and Virtual Clinical Trial Models and Increasing Strategic Licensing and Co-development Agreements Offer Growth Opportunities to Market Players The increasing adoption of decentralized and hybrid clinical trial models creates a significant growth opportunity for sponsors, CROs, and digital health providers in the non-alcoholic steatohepatitis clinical trials market. Remote patient monitoring, telemedicine, and electronic patient-reported outcomes improve recruitment, retention, and access to geographically diverse patient populations. This is expected to accelerate global trial execution while reducing operational costs and improving participant engagement.The rising number of licensing, co-development, and commercialization agreements creates significant growth opportunities for pharmaceutical companies and biotechnology firms. Large pharmaceutical companies are partnering with smaller innovators to access promising NASH drug candidates, share development risks, and accelerate global clinical programs. This trend is expected to expand late-stage trial activity, strengthen pipeline diversification, and increase cross-border collaborations.
July 2026 Madrigal Pharmaceuticals announced the grant of three new patents covering Rezdiffra (resmetirom), strengthening its intellectual property portfolio and extending protection for its MASH franchise.
September 2025 89bio announced that it had entered into a definitive merger agreement with Roche, under which Roche agreed to acquire the company for a total equity value of up to USD 3.5 billion, strengthening Roche's liver disease pipeline.
August 2025 Madrigal Pharmaceuticals received European Commission conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with MASH and moderate-to-advanced liver fibrosis, marking the first approved therapy for MASH in the European Union.